125 related articles for article (PubMed ID: 10474131)
1. Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin.
Rigamonti AE; Cella SG; Marazzi N; Müller EE
Eur J Endocrinol; 1999 Sep; 141(3):313-20. PubMed ID: 10474131
[TBL] [Abstract][Full Text] [Related]
2. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
Massoud AF; Hindmarsh PC; Brook CG
Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
Rigamonti AE; Marazzi N; Cella SG; Cattaneo L; Müller EE
J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide.
Rigamonti AE; Cavallera G; Bonomo S; Deghenghi R; Locatelli V; Cella SG; Müller EE
Eur J Endocrinol; 2001 Nov; 145(5):635-44. PubMed ID: 11720883
[TBL] [Abstract][Full Text] [Related]
5. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.
Massoud AF; Hindmarsh PC; Matthews DR; Brook CG
Clin Endocrinol (Oxf); 1996 May; 44(5):555-62. PubMed ID: 8762732
[TBL] [Abstract][Full Text] [Related]
6. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
[TBL] [Abstract][Full Text] [Related]
7. GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide.
Rigamonti AE; Bonomo SM; Cella SG; Müller EE
J Endocrinol; 2002 Sep; 174(3):387-94. PubMed ID: 12208658
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.
Arvat E; Di Vito L; Gianotti L; Ramunni J; Boghen MF; Deghenghi R; Camanni F; Ghigo E
Metabolism; 1997 Jan; 46(1):83-8. PubMed ID: 9005975
[TBL] [Abstract][Full Text] [Related]
9. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.
Maccario M; Arvat E; Procopio M; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
Metabolism; 1995 Jan; 44(1):134-8. PubMed ID: 7854159
[TBL] [Abstract][Full Text] [Related]
10. GH responsiveness to repeated GHRH or hexarelin administration in normal adults.
Sartorio A; Conti A; Ferrero S; Spada A; Faglia G
J Endocrinol Invest; 1995 Oct; 18(9):718-22. PubMed ID: 8719303
[TBL] [Abstract][Full Text] [Related]
11. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
[TBL] [Abstract][Full Text] [Related]
12. Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insensitive to GH-releasing hormone.
Giustina A; Bonfanti C; Licini M; Ragni G; Stefana B
Regul Pept; 1997 May; 70(1):49-54. PubMed ID: 9250581
[TBL] [Abstract][Full Text] [Related]
13. Hexarelin induced growth hormone release is influenced by exogenous growth hormone.
Massoud AF; Hindmarsh PC; Brook CG
Clin Endocrinol (Oxf); 1995 Nov; 43(5):617-21. PubMed ID: 8548947
[TBL] [Abstract][Full Text] [Related]
14. Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa.
Popovic V; Micic D; Djurovic M; Obradovic S; Casanueva FF; Dieguez C
Clin Endocrinol (Oxf); 1997 May; 46(5):539-43. PubMed ID: 9231048
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs.
Rigamonti AE; Cella SG; Marazzi N; Müller EE
Metabolism; 1999 Feb; 48(2):176-82. PubMed ID: 10024078
[TBL] [Abstract][Full Text] [Related]
16. Hexarelin stimulation of growth hormone release and mRNA levels in an infant and adult rat model of impaired GHRH function.
Torsello A; Luoni M; Grilli R; Guidi M; Wehrenberg WB; Deghenghi R; Müller EE; Locatelli V
Neuroendocrinology; 1997 Feb; 65(2):91-7. PubMed ID: 9067986
[TBL] [Abstract][Full Text] [Related]
17. The effects of a continuous infusion of hexarelin on pulsatile growth hormone release, growth axis and galanin gene expression and on the response of the growth axis to growth hormone-releasing hormone.
Conley LK; Brogan RS; Giustina A; Wehrenberg WB
Pituitary; 2000 May; 2(4):253-60. PubMed ID: 11081146
[TBL] [Abstract][Full Text] [Related]
18. The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man.
Micic D; Popovic V; Kendereski A; Peino R; Dieguez C; Casanueva FF
Clin Endocrinol (Oxf); 1996 Nov; 45(5):543-51. PubMed ID: 8977750
[TBL] [Abstract][Full Text] [Related]
19. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
[TBL] [Abstract][Full Text] [Related]
20. Modulation of growth hormone-releasing activity of hexarelin in man.
Arvat E; Gianotti L; Di Vito L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
Neuroendocrinology; 1995 Jan; 61(1):51-6. PubMed ID: 7731498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
